Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

DeepFusionCDR: Employing Multi-Omics Integration and Molecule-Specific Transformers for Enhanced Prediction of Cancer Drug Responses

TransCDR: a deep learning model for enhancing the generalizability of cancer drug response prediction through transfer learning and multimodal data fusion for drug representation

DeepCDR: a Hybrid Graph Convolutional Network for Predicting Cancer Drug Response

MAF-CDR: Multi-Omics Data Integration for Cancer-Drug Response Prediction Model

TransCDR: a deep learning model for enhancing the generalizability of drug activity prediction through transfer learning and multimodal data fusion

Prediction of Cancer Drug Effectiveness Based on Multi-Fusion Deep Learning Model

MMCL-CDR: enhancing cancer drug response prediction with multi-omics and morphology images contrastive representation learning

DRN-CDR: A cancer drug response prediction model using multi-omics and drug features

TCR: A Transformer Based Deep Network for Predicting Cancer Drugs Response

RedCDR: Dual Relation Distillation for Cancer Drug Response Prediction

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Deep learning assisted multi-omics integration for survival and drug-response prediction in breast cancer

DeepTTA: a transformer-based model for predicting cancer drug response

DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cancer Cell Lines

The prediction of drug sensitivity by multi-omics fusion reveals the heterogeneity of drug response in pan-cancer

DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration

An Ensemble Cascade Forest‐Based Framework for Multi‐Omics Drug Response and Synergy Prediction

Deep learning and multi-omics approach to predict drug responses in cancer

A Benchmark Study of Deep Learning-Based Multi-Omics Data Fusion Methods for Cancer.

MCMVDRP: a multi-channel multi-view deep learning framework for cancer drug response prediction

GraphCDR: a graph neural network method with contrastive learning for cancer drug response prediction